- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00005604
Interleukin-12 Plus Interleukin-2 in Treating Patients With Advanced Solid Tumors
Phase I Trial of Twice Weekly IV IL-12 Plus Low-Dose Subcutaneous IL-2 in Patients With Advanced Malignancies
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. To determine the toxicity profile and MTD of low-dose SC IL-2 administered in conjunction with BIW regimen of IV rhIL-12.
II. To determine the antitumor effects of combination therapy with IV rhIL-12 and SC IL-2.
III. To determine the impact low-dose SC IL-2 has on the magnitude and duration of in vivo immune activation induced by a BIW schedule of IV rhIL-12.
OUTLINE: This is a dose-escalation study.
Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks. Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12. On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week. Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients with disease response may continue treatment until complete response or disease progression.
Cohorts of 3-6 patients receive escalating doses of IL-12 and IL-2 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.
Patients are followed at 3 weeks.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Beth Israel Deaconess Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients must have a histologically confirmed solid tumor malignancy which is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; patients with hematologic malignancies will be excluded
- Patients must have advanced measurable or evaluable disease which is clearly progressive
- Patients must be ambulatory with good performance status (ECOG PS 0 or 1; Karnofsky PS 100-80%) and have an anticipated survival of at least 3 months
- Women of child bearing potential must have a negative pregnancy test and will be expected to use proven contraceptive methods while on protocol therapy; women who are breast-feeding are excluded from this study
- WBC > 4000/mm^3
- ANC > 1500/mm^3
- Platelet count > 100,000/mm^3
- Bilirubin < 1.5 mg/dl
- SGOT, SGPT < 2 x normal
- Creatinine < 1.5 mg/dl or calculated creatinine clearance >= 60 ml/min
- No evidence of congestive heart failure, symptoms of coronary artery disease, serious cardiac arrhythmias, or evidence of prior myocardial infarction on EKG
- No evidence of active infection which requires antibiotic therapy or history of treatment with IV antibiotics for a documented infection within 2 weeks of beginning treatment
- Patients must have recovered from the toxicity of prior therapy and have clearly progressive disease
- CHEMO, HORMONAL, AND RADIOTHERAPY There is a limit of two prior chemotherapy regimens which patients may have received; (patients who have received extensive prior cytotoxic therapy may no longer have adequate organ function and may not be eligible); at least 4 weeks must have elapsed from the end of previous chemotherapy, hormonal therapy, or radiotherapy (six weeks for nitrosoureas or mitomycin); concurrent chemotherapy, hormonal therapy or radiotherapy is not permitted; patients on steroids, including replacement therapy, will be excluded from the study
- BIOLOGICAL RESPONSE MODIFIERS No more than 2 prior BRM treatment regimens are permitted; prior immunotherapy should have been completed at least 4 weeks prior to beginning treatment on this protocol; prior therapy will IL-2 or rhIL-12 is allowable if >= 6 months have elapsed since the end of IL-2 treatment or if >= 12 months have elapsed since rhIL-12 therapy
- The patient must give signed informed consent prior to the initiation of therapy; patients with a history of major psychiatric illness must be judged able to fully understand the investigational nature of the study and the risks associated with therapy
Patients with the following problems will be considered ineligible:
Organ allografts
- Brain metastases
- Seizure disorders
- Patients known to be HIV positive are excluded based on the potential harm these agents may have on their underling immune function and the unknown effects of combination therapy with IL-12 and IL-2 on HIV viral replication; in addition, HIV infection, through its documented deleterious effects on lymphocyte number and function, may impair the patient's ability to respond to this form of cytokine-based immunotherapy
- Any medical condition likely to require use of corticosteroids during IL-12 therapy
- Autoimmune or rheumatologic disease
- Active (clinical or subclinical) hepatitis B or hepatitis C infection
- Any significant medical disease other than the malignancy felt by the investigator to place the patient at greater risk for developing a life-threatening toxicity from the therapy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Treatment (rhIl-12, IL-2)
Patients receive interleukin-12 (IL-12) IV on days 1 and 4 for 6 weeks.
Beginning on day 4 of the third week, patients receive interleukin-2 (IL-2) subcutaneously 1 hour before and 20 hours after each dose of IL-12.
On subsequent courses, IL-2 and IL-12 are administered on days 1 and 4 of each week.
Treatment continues for 6 weeks in the absence of disease progression or unacceptable toxicity.
Patients with disease response may continue treatment until complete response or disease progression.
|
Estudos correlativos
Dado SC
Outros nomes:
Dado IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
MTD defined as the dose level that is just below the dose on which at least 2 of 6 patients developed a dose-limiting toxicity (DLT) as assessed by CTC version 2.0
Prazo: 6 weeks
|
6 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Michael Atkins, Beth Israel Deaconess Medical Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Efeitos Fisiológicos das Drogas
- Agentes Anti-Infecciosos
- Agentes do Sistema Nervoso Periférico
- Antivirais
- Agentes anti-HIV
- Antirretrovirais
- Analgésicos
- Agentes do Sistema Sensorial
- Analgésicos, Não Narcóticos
- Agentes Antineoplásicos
- Fatores imunológicos
- Inibidores de angiogênese
- Agentes Moduladores da Angiogênese
- Substâncias de crescimento
- Inibidores de crescimento
- Adjuvantes Imunológicos
- Aldesleucina
- Interleucina-12
- Interleucina-2
Outros números de identificação do estudo
- NCI-2013-00049
- BIDMC #99-1332
- CDR0000067723 (Identificador de registro: PDQ (Physician Data Query))
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em análise laboratorial de biomarcadores
-
ORIOL BESTARDConcluídoTransplante Renal | Infecção por CMVEspanha, Bélgica
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Ainda não está recrutandoInfecções por HIV | Hepatite B
-
Bandim Health ProjectResearch Center for Vitamins and Vaccines, Statens Serum InstituteRescindidoMortalidade infantil | BCGGuiné-Bissau
-
McGill University Health Centre/Research Institute...Northwestern UniversityRecrutamentoApnéia da PrematuridadeCanadá
-
Postgraduate Institute of Medical Education and...Desconhecido
-
Riyadh Colleges of Dentistry and PharmacyKing Faisal Specialist Hospital & Research CenterDesconhecidoMucosite Oral